This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Blanchard, D. K. Articles by Djeu, J. Y. Search for Related Content PubMed PubMed Citation Articles by Blanchard, D. K. Articles by Djeu, J. Y.

Infiltration of Interleukin-2-inducible Killer Cells in Ascitic Fluid and Pleural Effusions of Advanced Cancer Patients

Departments of Medical Microbiology and Immunology [D. K. B., J. Y. D.] and Oncology [J. J. K., D. C., S. M. H.], University of South Florida College of Medicine and Community Cancer Center, St. Joseph's Hospital [J. G. S.], Tampa, Florida

Using ascitic fluid or pleural effusion obtained from 13 ovarian or metastatic breast cancer patients, we separated tumor cells from effusion-associated lymphocytes (EAL) with Percoll density centrifugation. Lymphocytes were incubated with recombinant interleukin 2 (IL-2) for 3–4 days and then assessed for tumoricidal activity in a ⁵¹chromium-release assay. The IL-2-activated EAL were found to lyse autologous fresh tumor cells, as well as allogeneic fresh tumor cells and FMEX tumor cells, a melanoma cell line which is resistant to natural killer cell activity but is sensitive to lysis by lymphokine-activated killer cells. There was little or no tumoricidal activity seen in freshly isolated EAL or in EAL which were cultured in medium without IL-2. Phenotypically, the IL-2-activated EAL were largely CD3-, although some cytolytic activity was found in CD3+ populations. Also, most activity was found in cells positive for CD2 (OKT11) and CD16 (Leu 11b), and negative for the monocyte marker Leu M3. These results indicate that the activated cell types found in EAL were predominantly natural killer/lymphokine-activated killer-like with a small contribution from T-cells. Finally, EAL were readily activated by IL-2 in medium containing autologous effusion fluid, indicating that in situ activation of tumoricidal activity by IL-2 can occur in the face of potentially inhibitory substances or cells that may exist in the effusions. Direct introduction of IL-2 may therefore be a potential therapeutic modality of effusion-forming cancers.

¹ To whom requests for reprints should be addressed, at Department of Medical Microbiology and Immunology, University of South Florida College of Medicine, P. O. Box 10, 12901 North 30th Street, Tampa, FL 33612.

Received 5/23/88. Revised 8/16/88. Accepted 8/18/88.

This article has been cited by other articles:

				Y.-Q. Chen, H.-Z. Shi, X.-J. Qin, W.-N. Mo, X.-D. Liang, Z.-X. Huang, H.-B. Yang, and C. Wu CD4+CD25+ Regulatory T Lymphocytes in Malignant Pleural Effusion Am. J. Respir. Crit. Care Med., December 1, 2005; 172(11): 1434 - 1439. [Abstract] [Full Text] [PDF]

				X-J. Qin, H-Z. Shi, Z-X. Huang, L-F. Kang, W-N. Mo, and C. Wu Interleukin-16 in tuberculous and malignant pleural effusions Eur. Respir. J., April 1, 2005; 25(4): 605 - 611. [Abstract] [Full Text] [PDF]

				K. Oshikawa, K. Yanagisawa, S. Ohno, S.-I. Tominaga, and Y. Sugiyama Expression of ST2 in Helper T Lymphocytes of Malignant Pleural Effusions Am. J. Respir. Crit. Care Med., April 1, 2002; 165(7): 1005 - 1009. [Abstract] [Full Text] [PDF]

				R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance Pharmacol. Rev., March 1, 2001; 53(1): 25 - 72. [Abstract] [Full Text] [PDF]

				D. P. J. Barton, D. K. Blanchard, C. Duan, W. S. Roberts, D. Cavanagh, S. DeCesare, and J. Y. Djeu Interleukin-12 Synergizes With Interleukin-2 to Generate Lymphokine-Activated Killer Activity in Peripheral Blood Mononuclear Cells Cultured in Ovarian Cancer Ascitic Fluid Reproductive Sciences, November 1, 1995; 2(6): 762 - 771. [Abstract] [PDF]